March 21, 2013
/PRNewswire/ -- Spherix Consulting, a division of ChromaDex® Corporation (OTCQB:CDXC) ("ChromaDex"), announced today that its Senior Science Director, Dr.
, has been appointed to the advisory board of the American Botanical Council (ABC). ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries and has been a member of the ABC for more than eight years.
While serving on the Advisory Board, Dr. Booth will be volunteering her time to peer review articles that appear in
and/or various ABC publications. Additionally,
editors typically seek feedback and advice from Advisory Board members on issues such as research questions, article ideas, ABC policies and book reviews. Dr. Booth's diverse training in the areas of organic/bio-organic chemistry, pharmacognosy, natural products, dietary supplements and cancer will aid in these duties during her term on the ABC Advisory Board.
Dr. Booth's primary areas of expertise are in the scientific evaluation of botanical dietary supplements, development of high-throughput screening assays and drug discovery. She also has experience in anticancer signal transduction pathways utilizing death receptors, estrogenic phytochemicals and optimizing in vitro bioassays for use with natural products. Her credentials include a Cancer Research Training Award Postdoctoral Fellow from NCI-Frederick,
and a Ph.D. in Pharmacognosy from the
University of Illinois at Chicago
"We are very pleased that Dr. Booth has been appointed to this important role with the ABC," said
, CEO and Founder of ChromaDex. "Throughout her career, Dr. Booth has demonstrated a commitment to advancing the natural products industry and this honor recognizes her expertise and leadership. ChromaDex is a proud supporter of the ABC and Dr. Booth's appointment will give her a new platform to convey her knowledge to a wider audience in support of natural product innovation."
is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products includes patented
pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40 percent cyanidin-3-glucoside; NutraGAC™, a Gac fruit powder rich in lycopene and beta-carotene; and pteroberry™, an organic blend of pterostilbene, cranberry and blueberry. ChromaDex is also in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property.
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag